

31st July, 2017

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on un-audited Consolidated Financial Results for the quarter ended 30th June, 2017

The presentation on un-audited Consolidated Financial Results for the quarter ended 30th June, 2017 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: As above



Q1 FY 2017-18



(1)

Consolidated Revenues for Q1 2017-18

(₹ Crore)

Particulars	Q1 1718	Q1 1617	Gr%
India	464	510	-9%
US	272	434	-37%
Brazil	181	167	8%
Germany	202	187	8%
Other	123	114	8%
Others (Incl contract Mfg.)	132	139	-5%
Total	1,374	1,551	-11%

